These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29752391)

  • 1. ISCHEMIA: Establishing the Primary End Point.
    Bangalore S; Maron DJ; Reynolds HR; Stone GW; O'Brien SM; Alexander KP; Hochman JS
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004791. PubMed ID: 29752391
    [No Abstract]   [Full Text] [Related]  

  • 2. Planning and Conducting the ISCHEMIA Trial.
    Maron DJ; Harrington RA; Hochman JS
    Circulation; 2018 Oct; 138(14):1384-1386. PubMed ID: 30354348
    [No Abstract]   [Full Text] [Related]  

  • 3. 'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures: Lessons from DEFER and FAME-2 for End Points in the ISCHEMIA Trial.
    Rajkumar CA; Nijjer SS; Cole GD; Al-Lamee R; Francis DP
    Circ Cardiovasc Qual Outcomes; 2018 Mar; 11(3):e004665. PubMed ID: 29530888
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative Effectiveness Trials of Imaging-Guided Strategies in Stable Ischemic Heart Disease.
    Shaw LJ; Phillips LM; Nagel E; Newby DE; Narula J; Douglas PS
    JACC Cardiovasc Imaging; 2017 Mar; 10(3):321-334. PubMed ID: 28279380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BARI 2D: headlines are not enough.
    King SB
    JACC Cardiovasc Interv; 2009 Aug; 2(8):809-10. PubMed ID: 19695556
    [No Abstract]   [Full Text] [Related]  

  • 6. Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?
    Cheng-Torres KA; Desai KP; Sidhu MS; Maron DJ; Boden WE
    Future Cardiol; 2016 Jan; 12(1):35-44. PubMed ID: 26696561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DECISION-CTO: A "negative" clinical trial? Really?
    Gutiérrez-Chico JL; Louvard Y
    Cardiol J; 2017; 24(3):231-233. PubMed ID: 28417448
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of ISCHEMIA in stable ischemic heart disease.
    Spilias N; Zorach B; Denby K; Ellis S
    Cleve Clin J Med; 2020 Jun; 87(7):401-409. PubMed ID: 32636193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midterm Safety and Efficacy of ABSORB Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent: An Updated Meta-Analysis.
    Ha FJ; Nerlekar N; Cameron JD; Bennett MR; Meredith IT; West NE; Brown AJ
    JACC Cardiovasc Interv; 2017 Feb; 10(3):308-310. PubMed ID: 28183474
    [No Abstract]   [Full Text] [Related]  

  • 11. Secondary prevention of ischaemic cardiac events.
    Sudlow C; Lonn E; Pignone M; Ness A; Rihal C
    Clin Evid; 2002 Jun; (7):124-60. PubMed ID: 12230641
    [No Abstract]   [Full Text] [Related]  

  • 12. Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review.
    Campbell RT; Willox GP; Jhund PS; Hawkins NM; Huang F; Petrie MC; McMurray JJ
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27162229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting clinical trials: the 'beautiful' case.
    Agewall S; Atar D
    Fundam Clin Pharmacol; 2009 Apr; 23(2):261-2. PubMed ID: 19236485
    [No Abstract]   [Full Text] [Related]  

  • 14. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Practice guidelines for therapy of patients with ischemic heart disease].
    Yokoyama M
    Nihon Naika Gakkai Zasshi; 2002 Mar; 91(3):991-1005. PubMed ID: 11985112
    [No Abstract]   [Full Text] [Related]  

  • 16. [Introduction to randomized trials: the choice of endpoint].
    Simon EG; Fouché CJ; Perrotin F
    Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939
    [No Abstract]   [Full Text] [Related]  

  • 17. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine.
    Ennezat PV; Le Jemtel T; Cosgrove S; Hallas J; Hansen MR
    Acta Cardiol; 2020 Feb; 75(1):10-19. PubMed ID: 30513258
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current management of stable ischemic heart disease].
    Escobar C; Divisón JA
    Semergen; 2017; 43(1):57-58. PubMed ID: 27084462
    [No Abstract]   [Full Text] [Related]  

  • 20. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.
    Shaw LJ; Weintraub WS; Maron DJ; Hartigan PM; Hachamovitch R; Min JK; Dada M; Mancini GB; Hayes SW; O'Rourke RA; Spertus JA; Kostuk W; Gosselin G; Chaitman BR; Knudtson M; Friedman J; Slomka P; Germano G; Bates ER; Teo KK; Boden WE; Berman DS
    Am Heart J; 2012 Aug; 164(2):243-50. PubMed ID: 22877811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.